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Two monoclonal antibodies (MoAbs), PAL-M1 and 
PAL-M2, are described that were selected to discrimi-
nate between melanomas and nevocellular nevi (NN) in 
frozen sections. MoAb P AL-M1 reacted with all 15 mel-
anoma metastases (MM), with 14 of 19 primary cuta-
neous melanomas (PCM), 9 of 35 dysplastic nevi (DN), 
and 2 of 26 NN. The 2 NN stained were removed from 
patients with the dysplastic nevus syndrome. MoAb 
P AL-M2 reacted with 9 of 15 MM, 5 of 19 PCM, 3 of 35 
DN, and did not. react with 26 NN after usual staining 
conditions. The proportion of melanocytic cells stained 
was low in DN and much higher in PCM and especially 
in MM. Staining in DN was restricted to intraepidermal 
or subepidermal nests of atypical melanocytes. In PCM, 
staining with P AL-M2 was observed only in tumors with 
a Breslow thickness of 0.76 mm or higher. PAL-M1 and 
P AL-M2 may be immunohistochemical markers for tu-
mor progression in melanocytic proliferations. 
In recent years many melanoma-associated monoclonal an-
tibodies (MAA) have been developed by several institutions [1-
6]. These antibodies recognize well-defined determinants, such 
as class I or class II major histocompatibility complex (MHC) 
antigens [7,8] and transferrin [9]. Other antibodies recognize 
partly defined determinants of which only the molecular weight 
is known, or undefined determinants [10] . Many MAA a re 
broadly reactive with both normal tissues and other tumors; 
others have a more restricted tissue distribution. These findings 
indicate that there is no absolute specific ity for melanoma cells. 
Often cross-reactivity with nevocellular nevi (NN), endothe-
lium, nerves, or sweat glands has been observed [6]. Due to this 
cross-reactivity, MAA that may be important for studying 
pathogenesis or prognosis of melanocytic proliferations are 
relatively scarce. They include monoclonal antibodies (MoAbs) 
against MHC antigens , because changes in expression have 
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Abbreviations: 
ON: dysplastic nevus 
MAA: melanoma-associated antibody 
MHC: major histocompatibility complex 
MM: melanoma metastasis 
MoAb: monoclonal antibodies 
NN: nevocellular nevus 
PCM: primary cutaneous melanoma 
RAM-HPO: rabbit antimouse conjugated to horseradish peroxi-
dase 
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been described between NN and primary cutaneous melanomas 
(PCM) in tissue sections [11- 13]. However, the diagnostic 
application of t hese a ntibodies is limited, because weak class I 
MHC expression may be present in NN, increasing in dysplas-
tic nevi (DN). Class II MHC expression mostly is present only 
locally in PCM [14) . Therefore, it was felt worthwhile to further 
develop MAA that discriminate between NN and PCM in tiss1..1e 
sections [15]. Two newly developed MAA, PAL-M,, and PAL-
M2, t hat were selected for this purpose are described. 
MATERIALS AND METHODS 
Preparation of Monoclonal Antibodies 
Homogenates of freshly obtained lymph node metastases of mela-
noma, proven by frozen section examination, were injected i.p. into 
BALB/c mice. Two booster injections of melanoma cells from 2 other 
patients were given 3 and 5 weeks after the first injection. Three days 
after the th ird injection the mice were sacrificed and spleen cells were 
isolated for cell fusion. Sp 2/0 myeloma cells were fused with t he spleen 
cells by the procedure of Kohler and Milstein {16] and cultu red in soft 
agar. Nitrocellulose filters coated with human lymphocytes or mela-
noma cells were prepared as described by Sharon et al [17]. After lO 
days the agar cultures were overlaid with these filters for 16 h. After 
removal t he filters were developed with rabbit antimouse conjugated 
to horseradish peroxidase (RAM-HPO) and stained with diaminobe11 _ 
zidine and H202. The clones positive on melanoma filters and negative 
on lymphocyte filters were picked and grown in suspension . Superna-
tants of the wells were screened by indirect immunopemxidase staining 
of melanoma metastasiS (MM) and NN m frozen sectw~s. To ~eve lap 
monoclonal cultures the wells contammg the cells producmg ant1bodies 
that discriminated between MM and NN were subcloned on agar plates. 
Two stable clones, PAL-M, and PAL-M2, that markedly stained M]\.1 
and did not stain NN in frozen sections were identified. 
Tissue Samples 
Samples ofNN, ON, PCM, MM, normal human skin, normal lymph 
nodes, and some human skin tumors or tumorlike conditions were 
removed from fresh surgical specimens, snap-frozen, and stored a t 
-70"C. The samples were classified on the basis of histopathologic 
examination of paraffin sections. Of the 26 NN, 5 were junctional, 16 
compound, and 5 dermal types. In 2 of these NN, histologic features <::lf 
congenital nevus were present. 
Cells 
Human melanoma cells were isolated from metastases and cultured 
in Dulbecco's Modified Eagle's Medium. Cultured human melanocytes 
were obtained from Dr. Arthur van der Kamp, Department of Ce}] 
Biology and Medical Genetics, Erasmus University Rotterdam Medical 
School, Rotterdam, The Netherlands. Cultured human keratinocytes 
were obtained from Dr. Maja Ponec, Department of Dermatology 
University Medical Center, Leiden, The Netherlands. For immunope~ 
roxidase studies, cells were seeded onto glass coverslips and cultured 
for 24 h. 
Immunoperoxidase Staining 
Indirect immunoperoxidase staining was done with supernatants on 
frozen tissue sections fixed with acetone as described by Nakane an.d 
Pierce [18], using RAM lg conjugated to horseradish peroxidase C\s 
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second antibody and 3-a mino-9-ethylca rbazole as substrate. Counter-
stain ing with hematoxylin was used. Staining of each lesion was per-
formed in duplicate. In 5 cases of NN and 5 cases of MM the incubation 
with staining solution containing aminoethylcarbazole was extended 
up to 30 min as compared to 5 min in normal conditions. 
Characterization of the Monoclonal Antibodies and the Determinants 
Recognized 
An Ouchterlony immunodiffusion assay was used to determine the 
immunoglobulin subclass of the a ntibodies PAL-M, and PAL-M2• 
Homogenates of MM positive with PAL-M 1 a nd PAL-M2 were analyzed 
by polyacrylamide gel electrophoresis as described by Maize! [19]. 
Binding of t he MoAbs to the proteins separated by gel electrophoresis 
was assayed by the immunoblot technique described by Towbin et a l 
[20]. 
RESULTS 
lmmunoperoxidase Staining on Tissue Sections 
MoAb PAL-M, (subclass IgG,) reacted with all15 MM, with 
14 of 19 PCM, 9 of 35 DN, and 2 of 26 NN (Table I) . Extending 
the incubation period with the sta ining solution containing 
aminoethylcarbazole to 30 min did not result in staining of NN 
that were negative after an incubation period of 5 min (Fig 1). 
Staining intensity was marked in most lesions. Heterogeneity 
of staining intensity within a lesion was evident (Fig 2). The 
staining pattern was diffuse cytoplasmic (Fig 3). The proportion 
TABLE I. Immunohistochemical staining results of monoclonal 
antibodies discriminating between melanomas and neuocellular nevi on 
frozen sections 
Cuta neous lesions 
Nevocellular nevib 
Dysplastic nevi 
Primary mela nomas 
Metastatic melanomas 
Seborrhoic keratoses 
Basocellula r carcinomas 
Squamous cell ca rcinomas 
Kerathoacanthoma 
Immunohistochemical 
s t.aininga 
PAL-M, PAL-M2 
2/26 0/26 
9/35 3/35 
14/ 19 5/19 
15/15 9/ 15 
0/3 0/3 
0/3 0/3 
0/3 0/3 
0/1 0/ 1 
• Numbers of posit ive lesions/numbers of lesions tested. 
b Five junctional, 16 compound, and 5 dermal nevi . 
FIG 1. Nevocellular nevus does not show staining with PAL-M,, 
even after prolonged incubation. In the basal epidermis locally melanin 
is observed (X 160, with hematoxylin countersta ining) . 
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FIG 2. Sta ining of primary cutaneous melanoma with PAL-M,. 
Heterogeneity in staining intensity is evident (X 200, with hematoxylin 
counterstaining). 
FIG 3. Staining of melanoma metastasis with PAL-M, . The staining 
pattern is diffuse cytoplasmatic ( X 400, with hematoxylin counterstain-
ing). 
of melanocytic cells stained was low in DN (Fig 4) and much 
higher in melanomas (Table II) . No staining was found in 
normal melanocytes or in t he other skin tumors or related 
conditions tested (Table I). Dendritic cells amid lymphohistio-
cytic infiltrates adjacent to nevoid lesions, and dendritic cells 
in lymph nodes stained with PAL-M1• Sebaceous glands were 
also positive. 
In PCM no relationship was found between tumor thickness 
and the proportion of tumor cells stained (Table III). The 2 
NN reacting with PAL-M, were derived from patients having 
the dysplastic nevus syndrome (Table IV). In DN no relation-
ship was found between staining results for PAL-M, (Table 
IV) and type of dysplastic nevus syndrome, history of mela-
noma, degree of atypia. 
MoAb PAL-M2 (subclass lgG 1) reacted with 9 of 15 MM, 5 
of 19 PCM, 3 of 35 DN, and did not react with 26 NN after 
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FIG 4. Local staining of dysplastic nevus with PAL-M, (arrows). 
Derma l melanophages (arrowheads) do not stain (X 200, with hema-
toxylin counterstaining). 
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usual staining conditions (Table I). Staining intensity was high 
in most lesions, especially in MM. The staining pattern was 
cytop lasmic with a finely granular appearance (Fig 5). The 
proportion of melanocytic cells stained was low in DN and 
much higher in melanomas (Table II) . No staining was found 
in normal melanocytes, nor in the other skin tumors or related 
conditions tested (Table I) . In adjacent skin no staining was 
found. After 15 min incubation with the staining solution 
TABLE IV. Staining of common nevocellular nevi and dysplastic nevi 
with PAL-M1 and PAL-M2 in relation to clinicopathologic properties 
Common nevocellular Dysplastic nevi 
nevi 
Clinicopathologic 
properties PAL-M, PAL-M2 PAL-M, PAL-M, 
Pos Neg Pos Neg Pos Neg Pos Neg 
DNS absent 0 20 0 18 0 0 0 0 
DNS familia l type 1 3 0 4 4 11 0 15 
DNS sporadic type 1 1 0 2 5 15 3 17 
No melanoma in pa- 0 22 0 23 6 17 0 23 
tients history 
Melanoma in patien ts 2 1 0 3 3 9 0 12 
history 
No marked atypia NA" NA NA NA 6 19 3 25 
Marked atypia NA NA NA NA 3 7 0 7 
aNA = not applicable. 
T ABLE II. Proportion of melanocytic cells per lesion and number of melanocytic lesions stained with PAL-M, and PAL-M2 
Percentage of staining 
melanocytic cell s 
0 
0- 1 
1- 20 
21-50 
51- 80 
81- 100 
Total number of 
les ions 
Common nevocellular 
nev i 
PAL-M, PAL-M 2 
24 26 
2" 0 
0 0 
0 0 
0 0 
0 0 
26 26 
a Two cases with t he dysplastic nevus syndrome. 
Dysplastic nevi Primary melanomas 
PAL-M, PAL-M2 PAL-M, PAL-M2 
26 32 5 14 
9 3 1 0 
0 0 3 1 
0 0 7 2 
0 0 3 2 
0 0 0 0 
35 35 19 19 
TABLE III. Primary cutaneous melanomas stained with PAL-M1 and PAL-M2 
PAL-M, 
Histologic Breslow Percentage Lesion Sex thickness Intensity Age djagnosis of tumor num ber (mm) of cells 
sta ined staining 
1 15 F MiS NA 21-50 3+ 
2 52 M MiS NA 0 
3 34 F SSM 0.31 21-50 2+ 
4 33 M SSM 0.50 21- 50 3+ 
5 34 F SSM 0.55 1- 20 3+ 
6 35 F SSM 0.60 21-50 + 
7 40 F SSM 0.64 0- 1 2+ 
8 31 F SSM 0.72 0 
9 76 F ALM 0.76 0 
10 45 M SSM 0.80 21-50 2+ 
11 57 M SSM 0.85 0 
12 85 F SSM 0.95 1- 20 + 
13 31 F SSM 1.00 51- 80 3+ 
14 28 M SSM 1.00 51-80 2+ 
15 51 F SSM 1.30 21-50 ± 
16 64 F MI 1.32 0 
17 36 F SSM 2.74 51- 80 3+ 
18 41 F SSM 2.82 21-50 2+ 
19 76 F SS M 2.90 1-20 + 
Key: MiS = melanoma in situ 
SSM = superfic ia l spread ing melanoma 
ALM = acro lent igino us melanoma 
MI = mela noma indeterminate 
Nl = not in terp retable 
NA = not applicable 
3+ = bright staining, 2+ = less bright staining, + = dull staining, 
± = weak sta inin g, - = absent staining 
Melanoma metastases 
PAL-M, PAL-M, 
0 6 
1 0 
4 3 
3 0 
4 4 
3 2 
15 15 
PAL-M, 
Percentage Intensity 
of tumor of 
cells 
stained staining 
0 
0 
0 
0 
0 
0 
0 
0 
0 
21-50 + 
0 
1-20 + 
0 
51-80 + 
0 
0 
51-80 2+ 
0 
21-50 2+ 
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FIG 5. Staining of melanoma metastasis with PAL-M2. The staining 
pattern is fi nely granular cytoplasmic (X 400, with hematoxylin coun -
terstaining). 
containing aminoethylcarbazole a weak staining in N N was 
found. 
In P CM, staining was not found in 9 lesions wit h a tumor 
t hickness of 0. 76 mm or less, but 5 ou t of 10 t h icker t umors did 
stain. (T able III) . Staining of DN was observed in 3 cases of 
t he sporadic type, t hat did not show marked atypia histologi-
cally (T able IV) . A series of other, noncutaneous malignant 
tumors showed staining with both PAL-M, and PAL-M2. Stain-
ing with one or both ant ibodies was a lso found in tubular or 
acinar epit helium of t he digestive and urogeni ta l t ract, and in 
germ inal centers of lymph nodes and spleen. The ant ibodies 
did not react on formalin-fixed pa raffi n sections. 
l mmunoperoxidase Staining on Cultured Cells 
PAL-M, and PAL-M2 reacted wit h both cul tured and freshly 
obtained melanoma cells in a granula r and diffu se cytoplasmic 
pattern . Sta ining of cul tured melanocytes was not fo und wit h 
P AL-M, and sporadically wit h PAL -M2. Keratinocytes and 
fibroblasts were negative with both an t ibodies. 
Molecular Weight of the A ntigens Recognized by the 
Monoclonal Antibodies 
Immunoblotting wit h PAL-M2 revealed two well -demarcated 
lines sit uated in t he 95- 100 kD region (Fig 6). No staining was 
obtained on immunoblots developed wit h PAL-M,_ 
DISCUSSION 
Two monoclona l ant ibodies, P AL-M, and P AL-M 2 disc rim-
inating between NN and melanomas in frozen sections have 
been selected. The difference in staining of PAL-M, between 
t he vast majori ty of NN and melanomas may be due to t he 
absence of t he ant igen recognized by t he monoclon a l ant ibody 
in those NN because staining was n ot observed, even a fter 
extension of t he immunohistochemic101 l staining incubation . On 
t he other hand, t he ant igen recognized by PAL-M 2 appears to 
be present in NN in a very low quant ity, because staining could 
b e demonstrated only after amplification. The molecular weight 
of the ant igen recognized by P AL- M, could not be determined 
in immunoblotting. P AL-M2 recognizes 2 ant igens wit h a mo-
lecular weight in t he region of 95- 100 kD. This indicates t hat 
P AL-M2 recogni zes different ant igen s t han t he well -known 
melanoma-associated MoAb recogni zing P 97 (1] . The distri -
bution on t issue sections of t he antigen recognized by PAL-M, 
86 -
60 -
40 - -
29-
= ~95 
FIG 6. lmmunoblots of PAL-M, and PAL-M2 on lysates of a MM 
positive in immunohistochemical stai ning. Lane a: marker proteins (gel 
sta ined with Coomassie blue). Lane b: staini ng with PAL-M ,. Lane c: 
sta ining wi th PAL-M2 • 
or P AL-M2 is diffe ren t from that of t he other ant ibodies men -
tioned [1] and of MHC ant igens [21,22]. As t he tissue distri -
but ion was not restricted to malignant melanoma or other 
malignant t umors, it is apparent t hat PAL-M, and PAL-M2 
are not specific for ma lignant t ransformation. H owever, in 
melanocytic lesions t hese antibodies may be immunohisto-
chemical markers fo r tumor progression. T his is illustrated by 
the fact t hat both an tibodies, especially PAL-M" show very 
local staining of DN and an increased proportion of positive 
melanocytic cells in P CM and MM . Furthermore, staining with 
P AL-M2 was observed only in PCM with a Breslow t hickness 
of 0.76 mm or higher. Any prognostic implications of staining 
wi th P AL-M, and PAL-M2, in PCM still have to be established, 
by correlation wit h long-term fo llow-up data. 
Staining in DN was restricted to intraepidermal or subepi-
dermal nests of atypical melanocytes, supporting t he view t hat 
the junctiona l component of DN bears t he malignant poten t ial 
(23- 25]. We note t hat t he 2 NN that reacted wit h P AL-M , 
were derived from patien ts with t he dysplastic nevus syndrome. 
This may indicate t hat an t igenic changes associated with early 
malignant t ransformation precede morphologic changes as re-
fl ected by atypia. 
However , no relation could be established between sta ining 
of DN wit h t he MoAbs and the type of dysplastic nevus 
syndrome (i .e., familial or sporadic), degree of atypia, or history 
for melanoma. The immunohistochemical fi ndings of t his study 
illustrate t he fact that cells bearing some characteristics of 
malignant cells can be found in premalignant conditions [26]. 
These cells may develop into cells wit h full malignant potential. 
Further work is needed to characterize such cells. Possibly 
MoAbs like P AL-M, and P AL-M2 wit h a propensity to prefer-
ent ially stain MM can be used to ident ify subpopulations of 
tumor cells with a high malignant poten t ia l. 
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